“We hereby inform that Sterling Biotech Ltd is still in the process of completing certain conditions precedent of the BTA and hence the company and Sterling Biotech Ltd have executed a letter to extend the closing date by September 30, 2026. In view of the same, the transaction is expected to be completed on or before September 30, 2026,” according to a stock exchange filing.
The transaction is now expected to be completed on or before September 30, 2026. The company subsequently informed on December 24, 2025, that both parties had mutually agreed to extend the closing date to June 30, 2026.
ALSO READ | Zydus Life Share Buyback: All you need to know as a shareholder
In June this year, Zydus Lifesciences received a warning letter from the US Food and Drug Administration (USFDA) on Wednesday, June 3, for its formulation manufacturing facility in Baddi, Himachal Pradesh.
In an exchange filing, the drugmaker said the warning letter relates to a request for records under Section 704(a)(4) of the US Federal Food, Drug and Cosmetic Act and does not stem from an on-site inspection by the USFDA.
According to Zydus, the communication refers to technical observations regarding the use of purified talc that did not meet the current United States Pharmacopeia (USP) requirements. The company said it does not expect the warning letter to have any impact on current operations or supplies from the Baddi facility.
ALSO READ | Zydus Life jumps 5% on ₹1,100 crore share buyback; Q4 results beat street estimates
Zydus noted that the USFDA last inspected the Baddi plant in August 2025. Following the inspection, the company received an Establishment Inspection Report (EIR) in October 2025, with the facility classified under the Voluntary Action Indicated (VAI) category.
The company said it is working with the USFDA to complete the required remediation measures and will respond to the regulator within the stipulated timelines.
Shares of Zydus Lifesciences Ltd ended at ₹1,121.45, up by ₹1.81, or 19.95%, on the BSE.
ALSO READ | Zydus Lifesciences shares gain nearly 7% on strong US growth outlook; Check price targets
